BLAINJECTIONINJECTABLE
Approved
May 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
15
Clinical Trials (5)
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
Started Apr 2017
41 enrolled
Relapsing-Remitting Multiple Sclerosis (RRMS)
Daclizumab Japanese PK Study
Started Oct 2013
56 enrolled
Healthy
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
Started Nov 2011
133 enrolled
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis
Started May 2010
1,841 enrolled
Relapsing-Remitting Multiple Sclerosis
Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis
Started Mar 2010
410 enrolled
Relapsing-Remitting Multiple Sclerosis